Triterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes
Author Information
Author(s): Li Dawei, Lin Yuxin, Lv Xia, Wu Yuzhuo, Han Chaoyan, Cao Peng, Zhang Guixin, Leng Aijing, Zhou Jian, Wang Chao
Primary Institution: Dalian Medical University
Hypothesis
The study investigates the inhibitory effects of triterpenoids from Ganoderma lucidum on cytochrome P450 enzymes and their potential to interfere with the metabolism of clinical drugs.
Conclusion
G. lucidum has broad inhibitory effects on CYPs, with triterpenoids as the main bioactive constituents, which may lead to potential drug-drug interactions.
Supporting Evidence
- The dichloromethane extract of G. lucidum inhibited various CYP450 subtypes in vitro.
- Triterpenoids were identified as the main constituents of the dichloromethane extract.
- Compounds 6 and 25 exhibited interference with the metabolism of 16 drugs through CYP inhibition.
- Most lanostane triterpenoids showed strong affinity for CYP 1A2.
- Ganodrol C (compound 25) displayed broad inhibitory effects against multiple CYPs.
Takeaway
This study found that a mushroom called Ganoderma lucidum can stop certain enzymes in our body that help break down medicines, which could change how those medicines work.
Methodology
The study used in vivo activity assays, LC-MS for chemical identification, and in silico docking analysis to evaluate the inhibitory effects of G. lucidum on CYP enzymes.
Limitations
The study primarily focused on rat models, which may not fully represent human metabolism.
Participant Demographics
Male SD rats, weighing 220g ± 20g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website